Compounds > cresyl glycidyl ether
Page last updated: 2024-12-05

cresyl glycidyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cresyl glycidyl ether: RN given refers to cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16606
CHEMBL ID3249573
SCHEMBL ID187051
MeSH IDM0134072

Synonyms (45)

Synonym
2,3-epoxypropyl-p-tolyl ether
p-cresyl glycidyl ether
nsc-112255
2186-24-5
nsc112255
oxirane, ((4-methylphenoxy)methyl)-
1,2-epoxy-3-(p-tolyloxy)propane
ccris 2637
nsc 112255
((4-methylphenoxy)methyl)oxirane
cresyl glycidyl ether
brn 0117187
((p-tolyloxy)methyl)oxirane
glycidyl p-tolyl ether
einecs 218-574-8
glycidyl 4-methylphenyl ether
p-methylphenyl glycidyl ether
propane, 1,2-epoxy-3-(p-tolyloxy)-
p-cresol glycidyl ether
2-[(4-methylphenoxy)methyl]oxirane
AKOS000200286
FT-0693809
A815715
EN300-09213
26447-14-3
FT-0638607
2-p-tolyloxymethyl-oxirane
AB02014
CHEMBL3249573
AKOS016051063
SCHEMBL187051
2-[(4-methylphenoxy)methyl]-oxirane
CUFXMPWHOWYNSO-UHFFFAOYSA-N
2,3-epoxypropyl p-tolyl ether
oxirane, [(4-methylphenoxy)methyl]-
p-methylphenol glycidyl ether
2-((p-tolyloxy)methyl)oxirane
DTXSID3024863
Z57046213
J-016428
mfcd00046991
2-(p-tolyloxymethyl)oxirane
AS-10315
N12247
CS-0307861
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1132582Hypocholesteremic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered for 10 days measured 24 hrs after last dose by Liebermann-Burchard method (Rvb = 100 +/- 10%)1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID1132581Hypocholesteremic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered for 4 days measured 24 hrs after last dose by Liebermann-Burchard method (Rvb = 100 +/- 8%)1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID1132583Hypocholesteremic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered for 16 days measured 24 hrs after last dose by Liebermann-Burchard method (Rvb = 100 +/- 9%)1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID11325861-Octanol-water partition coefficient, log P of the compound by UV spectrophotometer1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID1132585Estrogenic activity in Sprague-Dawley rat at 10 mg/kg/day, po1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID1132584Toxicity in Sprague-Dawley rat at 10 mg/kg/day, po1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.80 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index32.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (28.57%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2,2-bis(4-glycidyloxyphenyl)propane
2,2-bis(4-glycidyloxyphenyl)propane: structure		2.4120diarylmethane
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		1.9510aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
ethylenediamine
ethylenediamine: RN given refers to parent cpd; edamine is the recommended contraction for the ethylenediamine radical. ethylenediamine : An alkane-alpha,omega-diamine in which the alkane is ethane.		6.9810alkane-alpha,omega-diamineGABA agonist
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		1.9810aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
1,6-hexanediol diglycidyl ether
1,6-hexanediol diglycidyl ether: structure in first source		2.4120
ConditionIndicatedRelationship StrengthStudiesTrials
Allergic Contact Dermatitis
[description not available]		06.9810
Dermatitis, Occupational
A recurrent contact dermatitis caused by substances found in the work place.		01.9810
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		01.9810